This biopharma stock has sold off 48% this year, but the firm sees upside potential of 137% ahead.
You are here: Home / Here’s why this under-the-radar biopharma stock could leap nearly 140%, Goldman Sachs says
Market News and Views
This biopharma stock has sold off 48% this year, but the firm sees upside potential of 137% ahead.